Treatment with Diacomit should only be given under the supervision of a doctor who specialises in the diagnosis and management of epilepsy in children (a paediatrician or paediatric neurologist). The recommended dose is 50 mg per kilogram bodyweight, divided into two or three doses during the day.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000664/human_med_000742.jsp&mid=WC0b01ac058001d124
What benefit has Diacomit shown during the studies? More patients responded to treatment with Diacomit than to placebo. In the first study, 71% of the patients taking Diacomit responded to treatment (15 out of 21), compared with 5% of the placebo group (1 out of 20).
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000664/human_med_000742.jsp&mid=WC0b01ac058001d124
What is the risk associated with Diacomit? The most common side effects with Diacomit (seen in more than 1 in 10 patients) are loss of appetite, weight loss, insomnia (difficulty sleeping), drowsiness, ataxia (inability to co‑ordinate muscle movements), hypotonia (low muscle strength) and dystonia (muscle disorders).
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000664/human_med_000742.jsp&mid=WC0b01ac058001d124
This research was generated by the preliminary Dravet syndrome patient registry launched in 2008 and was submitted to be used for application of Orphan Drug Designation for stiripentol in the United States. Stiripentol was granted Orphan Drug Designation in November 2008.
http://www.ice-epilepsy.org/stiripentol-use-in-children.html
What is Diacomit used for? Diacomit is used in children with a very rare type of epilepsy called ‘severe myoclonic epilepsy in infancy’ (SMEI), also known as Dravet’s syndrome. This type of epilepsy first appears in young children during the first year of life.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000664/human_med_000742.jsp&mid=WC0b01ac058001d124
For example, in Internet Explorer, you can go to the Tools/Internet options/Security and Privacy Tabs to adapt the browser to your expectations. If you use different computers in different locations you will need to ensure that each browser is adjusted to suit your cookie preferences.
http://www.diacomit.eu/
DIACOMIT® is the only antiepileptic drug to have clinically shown its efficacy in Dravet syndrome patients by two double blind placebo controlled trials. DIACOMIT® is available in dosage of 250mg and 500mg, both in hard capsules and powder for oral suspension in sachets.
http://www.diacomit.eu/
I understand. Use of cookies. Certain BIOCODEX websites may employ an industry-wide technology called cookies. A cookie is a text-only string of information that a website transfers to the cookie file of the browser on your computer's hard disk so that the website can remember who you are.
http://www.diacomit.eu/
Diacomit is an anti‑epileptic medicine that contains the active substance stiripentol. It is available as capsules and sachets (250 and 500 mg). The sachets contain a powder that is used to make up an oral suspension (a liquid with solid particles in it).
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000664/human_med_000742.jsp&mid=WC0b01ac058001d124
Example: Elliot took 250 mg of stiripentol three times a day = total daily dose = 750 mg. Please select from the list below the final total daily dose of stiripentol that was effective and tolerated by the child. Example: Elliot took 250 mg of stiripentol three times a day = total daily dose = 750 mg. After a month, Elliot presented with a one hour episode of status epilepticus. Neurologist increased the dose to 500 mg twice a day and 250 mg at bedtime over the next three months.
http://www.ice-epilepsy.org/stiripentol-use-in-children.html
what is diacomit
Diacomit is the only antiepileptic drug to have clinically shown its efficacy in Dravet syndrome patients by two double blind placebo controlled trials. Diacomit is the only anti-epileptic drug to have clinically shown its efficacy in Dravet syndrome patients by two double blind placebo controlled trials.